PPP2R1B — Protein Phosphatase 2 Regulatory Subunit A Beta

PPP2R1B — Protein Phosphatase 2 Regulatory Subunit A Beta

Path: `/genes/ppp2r1b` Tags: `section:genes`, `kind:gene`, `topic:phosphatase`, `topic:signal-transduction`, `topic:tauopathy`, `topic:Alzheimer's-disease`

Overview

PPP2R1B encodes the beta isoform of the regulatory subunit A (also known as PR65 or scaffold subunit) of protein phosphatase 2A (PP2A), a major serine/threonine phosphatase critical for tau dephosphorylation in the brain[@liu2005]. PP2A dysfunction is centrally implicated in Alzheimer's disease (AD) and related tauopathies, where reduced phosphatase activity leads to hyperphosphorylation of the microtubule-associated protein tau and subsequent neurofibrillary tangle formation[@gong2006]. The PP2A holoenzyme is a heterotrimeric complex comprising a catalytic subunit (PP2A-C), a structural subunit (PP2A-A, encoded by PPP2R1A or PPP2R1B), and one of multiple regulatory subunits (PP2A-B) that together determine substrate specificity, subcellular localization, and catalytic activity[@xing2006]. PPP2R1B provides essential structural scaffolding for PP2A holoenzyme assembly, and genetic variants in this gene have been associated with altered AD risk and disease progression.

<div class="infobox infobox-gene">

PPP2R1B — Protein Phosphatase 2 Regulatory Subunit A Beta

Path: `/genes/ppp2r1b` Tags: `section:genes`, `kind:gene`, `topic:phosphatase`, `topic:signal-transduction`, `topic:tauopathy`, `topic:Alzheimer's-disease`

Overview

PPP2R1B encodes the beta isoform of the regulatory subunit A (also known as PR65 or scaffold subunit) of protein phosphatase 2A (PP2A), a major serine/threonine phosphatase critical for tau dephosphorylation in the brain[@liu2005]. PP2A dysfunction is centrally implicated in Alzheimer's disease (AD) and related tauopathies, where reduced phosphatase activity leads to hyperphosphorylation of the microtubule-associated protein tau and subsequent neurofibrillary tangle formation[@gong2006]. The PP2A holoenzyme is a heterotrimeric complex comprising a catalytic subunit (PP2A-C), a structural subunit (PP2A-A, encoded by PPP2R1A or PPP2R1B), and one of multiple regulatory subunits (PP2A-B) that together determine substrate specificity, subcellular localization, and catalytic activity[@xing2006]. PPP2R1B provides essential structural scaffolding for PP2A holoenzyme assembly, and genetic variants in this gene have been associated with altered AD risk and disease progression.

<div class="infobox infobox-gene">

| Property | Value |
|----------|-------|
| Gene Symbol | PPP2R1B |
| Full Name | Protein Phosphatase 2 Regulatory Subunit A Beta |
| Chromosomal Location | 11q23.2 |
| NCBI Gene ID | 5519 |
| OMIM ID | 616982 |
| Ensembl ID | ENSG00000137713 |
| UniProt ID | P30101 |
| Encoded Protein | PP2A subunit A beta (PR65-beta) |
| Protein Family | HEAT repeat family |
| Associated Diseases | Alzheimer's disease, progressive supranuclear palsy, tauopathies, various cancers |

</div>

Introduction

Protein phosphatase 2A (PP2A) represents one of the most important serine/threonine phosphatases in eukaryotic cells, accounting for the majority of tau dephosphorylation activity in the brain. The PP2A holoenzyme is a sophisticated molecular machine composed of three distinct subunits that assemble to form a functional phosphatase complex. The catalytic subunit (PPP2CA or PP2A-C) contains the active site responsible for removing phosphate groups from phosphorylated serine and threonine residues on target proteins including tau. The structural subunit (PPP2R1A or PPP2R1B, also known as PR65) forms a scaffold consisting of 15 tandem repeat sequences arranged in an armadillo-like repeat structure that connects the catalytic and regulatory subunits. This scaffolding subunit is essential for maintaining the proper conformation of the holoenzyme and for facilitating the dynamic exchange of regulatory subunits that determine PP2A function in different cellular contexts.

PPP2R1B encodes the beta isoform of the PP2A structural subunit A, while PPP2R1A encodes the alpha isoform. Together, these two genes provide the structural scaffold for PP2A holoenzyme assembly throughout the body. The beta isoform has distinct tissue distribution patterns compared to the alpha isoform, with specific expression in brain tissue and other organs. The two isoforms are not simply redundant copies but serve specialized functions in different cellular contexts, and alterations in either isoform can contribute to disease pathogenesis. In the central nervous system, both isoforms are expressed, but their relative abundance varies across brain regions and during development.

PP2A Structure and Holoenzyme Assembly

The PP2A holoenzyme represents a sophisticated molecular machine whose proper assembly is essential for phosphatase activity toward physiological substrates including tau. The structural subunit encoded by PPP2R1B forms a horseshoe-shaped scaffold consisting of 15 tandem repeat sequences that provide multiple interaction surfaces for binding both the catalytic subunit and regulatory B-subunits simultaneously[@xing2006]. This architecture allows the dynamic exchange of regulatory subunits that determine PP2A function in different cellular contexts, making the structural subunit critical for proper holoenzyme composition.

The assembly of the PP2A holoenzyme is regulated by several additional proteins that facilitate proper subunit pairing and post-translational modification. The PP2A methyltransferase (PRMT5) catalyzes the C-terminal methylation of the catalytic subunit, which is required for high-affinity binding of most regulatory subunits. Conversely, the PP2A methylesterase (PME-1 or PPME1) removes this methyl group, promoting holoenzyme disassembly and providing a mechanism for dynamic regulation of PP2A composition. The interaction between these enzymes and the PP2A holoenzyme creates a methylation-demethylation cycle that controls the availability of catalytically active phosphatase complexes for specific cellular functions.

The regulatory subunit (collectively termed B-subunits or PP2A-B) represents the most diverse component of the PP2A holoenzyme, with multiple isoforms encoded by distinct genes and alternatively spliced variants providing tremendous functional diversity. These regulatory subunits determine substrate specificity by directly binding to target proteins and positioning them for dephosphorylation by the catalytic subunit. In the context of tau dephosphorylation, specific regulatory subunits such as the Bα (PPP2R2A) and Bβ (PPP2R2B) isoforms are particularly important for targeting PP2A to tau in the brain, and alterations in the expression or function of these regulatory subunits contribute to reduced tau dephosphorylation in AD[@xu2013].

PPP2R1B in Tau Dephosphorylation

PP2A accounts for approximately 70% of the total tau dephosphorylation activity in brain tissue, making it the primary phosphatase responsible for removing phosphate groups from hyperphosphorylated tau[@liu2005]. The structural subunit encoded by PPP2R1B is essential for proper holoenzyme assembly that enables efficient tau dephosphorylation. PP2A efficiently dephosphorylates tau at most disease-relevant phosphorylation sites, including those targeted by GSK-3β and CDK5. The specificity of PP2A for tau dephosphorylation is determined by the composition of the PP2A holoenzyme, with specific regulatory B-subunits facilitating the interaction between PP2A and tau.

The dephosphorylation of tau by PP2A restores its microtubule-binding capacity and promotes microtubule assembly, thereby counteracting the pathogenic effects of tau hyperphosphorylation. Importantly, PP2A can dephosphorylate tau that has been phosphorylated at multiple sites, suggesting it can processively remove phosphate groups from hyperphosphorylated tau molecules. The structural subunit plays a critical role in positioning the catalytic subunit relative to the regulatory B-subunit and tau substrate, making PPP2R1B expression essential for this process.

Recent studies have employed proteomic approaches to identify specific PP2A holoenzyme compositions that are most effective for tau dephosphorylation[@park2019]. Different regulatory subunit isoforms show varying capacities for tau dephosphorylation, and identifying the optimal holoenzyme composition has led to more targeted therapeutic approaches. Studies are also examining the role of post-translational modifications of tau in regulating its interaction with PP2A, as specific phosphorylation patterns may affect the efficiency of dephosphorylation.

Disease Associations

Alzheimer's Disease

Alzheimer's disease is characterized by the accumulation of extracellular amyloid-beta plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau. The "tau hypothesis" of AD pathogenesis proposes that tau hyperphosphorylation and aggregation are central events in neurodegeneration. PP2A plays a central role in this context, as reduced PP2A activity in AD brain tissue leads to impaired tau dephosphorylation and contributes to the formation of neurofibrillary tangles[@iqbal2009].

Multiple studies have documented reduced PP2A activity in AD brain tissue compared to age-matched controls. This reduction in activity has been observed in multiple brain regions affected by AD pathology, including the hippocampus and frontal cortex, and correlates with the severity of neurofibrillary pathology[@vogelsang2019]. The mechanisms underlying reduced PP2A activity in AD are multifactorial, involving changes in the expression and post-translational modification of PP2A subunits, increased association with inhibitory proteins, and altered holoenzyme composition. Together, these changes shift the balance toward tau hyperphosphorylation and contribute to the progression of tau pathology.

The expression of the PP2A Bα regulatory subunit (PPP2R2A) is reduced in AD brain, which may impair the targeting of PP2A to tau substrates[@chen2018]. Methylation of PP2A-C is also reduced, potentially due to altered activities of PRMT5 and PME-1, leading to impaired holoenzyme assembly. The levels of the PP2A inhibitor SET are elevated in AD brain tissue, and SET has been shown to colocalize with neurofibrillary tangles, suggesting a direct role in tau pathology[@scroggins2019]. Additionally, increased phosphorylation of PP2A-C at inhibitory tyrosine residues has been documented in AD.

Genetic variants in PPP2R1B have been associated with altered AD risk in several studies. While the exact mechanisms by which these variants influence disease risk remain under investigation, they likely affect PP2A holoenzyme assembly or function, leading to subtle changes in tau phosphorylation homeostasis. These findings suggest that PPP2R1B may serve as a genetic modifier of AD progression in carriers of risk variants.

Other Tauopathies

PP2A dysfunction contributes to tau pathology in several other neurodegenerative diseases beyond AD. In progressive supranuclear palsy (PSP), PP2A alterations have been documented that may contribute to the characteristic tau pathology observed in this disease[@togo2002]. Similarly, corticobasal degeneration (CBD) and frontotemporal dementia with tau pathology (FTD-Tau) involve mechanisms of PP2A dysregulation that may differ from AD. Understanding the disease-specific contributions of PP2A dysfunction could lead to personalized therapeutic approaches for different tauopathy subtypes.

Cancer Associations

Beyond neurodegenerative diseases, PPP2R1B has been implicated in various cancers. PP2A functions as a tumor suppressor by regulating cell cycle progression, and alterations in PP2A subunits can contribute to oncogenic transformation. The PPP2R1B gene has been found mutated or altered in some tumors, suggesting its role in cancer pathogenesis extends beyond neurodegeneration.

Expression Pattern

PPP2R1B exhibits high expression in the brain, particularly in the cerebral cortex and hippocampus, which are brain regions critically affected in Alzheimer's disease. The protein is localized primarily in the cytosol, where it participates in PP2A holoenzyme assembly. Both alpha and beta isoforms of the PP2A structural subunit are expressed in the brain, but their relative abundance varies across brain regions and cell types.

The beta isoform has distinct tissue distribution compared to the alpha isoform. While PPP2R1A is ubiquitously expressed, PPP2R1B shows more restricted expression patterns with high levels in brain and testis. This tissue-specific expression suggests that PPP2R1B may serve specialized functions in neuronal cells that are not fully compensated by the alpha isoform.

Regulation of PP2A Activity

The activity of PP2A is subject to extensive regulation at multiple levels, including post-translational modifications of the catalytic subunit, interaction with endogenous inhibitor proteins, and control of holoenzyme assembly through methylation dynamics. These regulatory mechanisms provide tight control over PP2A function in response to cellular signals and ensure proper spatial and temporal regulation of phosphatase activity. In the context of tau dephosphorylation, dysregulation of these control mechanisms contributes to reduced PP2A activity and the development of tau pathology in AD.

The methylation of PP2A-C at the C-terminal Leu309 residue by PRMT5 is essential for the assembly of most PP2A holoenzymes containing regulatory B-subunits. This methylation creates a hydrophobic surface that facilitates high-affinity binding between the catalytic and regulatory subunits. The methylation status of PP2A is dynamically regulated by the opposing activities of PRMT5 and the methylesterase PME-1, which removes the methyl group to promote holoenzyme disassembly. In AD brain tissue, reduced methylation of PP2A-C has been reported, which may contribute to impaired holoenzyme assembly and reduced tau dephosphorylation activity[@sontag2012].

Several endogenous inhibitor proteins specifically target PP2A and modulate its activity toward tau and other substrates. The protein CIP2A (cancerous inhibitor of PP2A) binds to and inhibits PP2A activity, and elevated CIP2A expression has been documented in AD brain tissue[@khanna2016]. SET, also known as I2PP2A (inhibitor 2 of PP2A), is another potent PP2A inhibitor that binds to the catalytic subunit and blocks its active site. SET is normally localized to the nucleus but can translocate to the cytoplasm under certain conditions, where it can inhibit PP2A-mediated dephosphorylation of cytoplasmic substrates including tau.

Phosphorylation of PP2A-C at specific residues provides another layer of regulation over phosphatase activity. Phosphorylation at Tyr307 by Src family kinases inhibits PP2A activity, while phosphorylation at Thr304 by ATM or other kinases can also suppress catalytic function[@jun2020]. These phosphorylation events provide mechanisms for signal transduction pathways to modulate PP2A activity in response to cellular stimuli.

Synaptic Function and Cognitive Decline

The consequence of reduced PP2A activity in AD extends beyond tau hyperphosphorylation to include effects on multiple PP2A substrates that regulate neuronal function and survival. PP2A dephosphorylates multiple proteins involved in synaptic plasticity, cytoskeletal dynamics, and apoptotic pathways, and dysregulation of these functions may contribute to synaptic loss and neuronal death in AD[@liu2017].

PP2A plays critical roles in regulating synaptic plasticity through modulation of NMDA receptor and AMPAR trafficking. The phosphatase dephosphorylates several synaptic proteins that control neurotransmitter release and receptor localization at synapses. By regulating these processes, PP2A contributes to learning and memory functions that are prominently impaired in AD. The broader impact of PP2A dysregulation suggests that restoring PP2A activity could have beneficial effects beyond simply promoting tau dephosphorylation.

Animal models have provided important insights into the role of PP2A in tau pathology and synaptic function. Genetic reduction of PP2A activity in mice leads to tau hyperphosphorylation and aggregation, while pharmacological activation of PP2A can reduce tau pathology in models of AD[@liu2018]. These findings support the therapeutic potential of targeting PP2A in AD and other tauopathies.

Therapeutic Implications

The central role of PP2A in regulating tau phosphorylation makes it an attractive target for therapeutic intervention in AD and related tauopathies. Strategies aimed at restoring PP2A activity or removing barriers to its function could promote tau dephosphorylation and potentially halt or reverse the progression of neurofibrillary pathology[@vickers2015]. Several therapeutic approaches are being explored, including direct activation of PP2A, modulation of PP2A regulatory proteins, and restoration of normal PP2A post-translational modifications.

Direct activation of PP2A can be achieved using small molecule activators that bind to the phosphatase complex and enhance its catalytic activity. Several compounds have been identified that can activate PP2A, including the antibiotic nalidixic acid and its derivatives, as well as natural products such as curcumin and its analogs[@wu2020]. These compounds have shown efficacy in cellular and animal models of tauopathy, reducing tau phosphorylation and improving behavioral outcomes. However, the development of PP2A activators with suitable pharmacokinetic properties for clinical use remains a challenge.

Modulation of PP2A regulatory proteins represents an alternative therapeutic approach. Inhibition of PP2A inhibitors such as CIP2A or SET could restore PP2A activity and promote tau dephosphorylation. Small molecule inhibitors of SET have been identified and tested in preclinical models, with some success in reducing tau pathology. Similarly, strategies to promote PP2A methylation by enhancing PRMT5 activity or inhibiting PME-1 could improve holoenzyme assembly and function.

Gene therapy approaches targeting PP2A subunits represent a more direct strategy for restoring PP2A function. Viral delivery of PP2A catalytic subunit or regulatory subunit genes to the brain could increase PP2A expression and activity. However, the complexity of PP2A regulation and the potential for unintended effects on other PP2A substrates make this approach challenging.

Cross-links

• [PP2A Tau Phosphatase Pathway](/mechanisms/pp2a-tau-phosphatase-pathway) — Comprehensive pathway page on PP2A-mediated tau dephosphorylation
• [Tau protein](/proteins/tau) — PP2A dephosphorylates tau
• [Alzheimer's disease](/diseases/alzheimers-disease) — Associated neurodegenerative disease
• [PPP2R1A](/genes/ppp2r1a) — Related gene encoding the alpha isoform of PP2A subunit A
• [PPP2R2A](/genes/ppp2r2a) — PP2A regulatory subunit B alpha involved in tau dephosphorylation

See Also

• [Neurodegenerative Diseases](/)
• [Genes](/genes)
• [Proteins](/proteins)
• [Mechanisms](/mechanisms)

References